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Objective: Since development of a living donor bilateral obar transplantation 
protocol for patients with cystic fibrosis, our indications have expanded to 
include recipients with other diagnoses. Methods: We report on our experience 
in eight patients with primary pulmonary hypertension, postchemotherapy 
pulmonary fibrosis, bronchopulmonary dysplasia, idiopathic pulmonary fibro- 
sis, and obliterative bronchiolitis. The average age of the eight patients was 
19.1 years (range 9 to 40). The mean preoperative carbon dioxide tension for 
the four patients who did not have primary pulmonary hypertension was 92 
mm Hg (range 64 to 120 mm Hg), and the two patients with pulmonary fibrosis 
were intubated (one on high-frequency jet ventilation). Each recipient received 
a right lower lobe (n = 7) or middle lobe (n = 1) and a left lower lobe (n = 8) 
from a total of 16 donors representing various combinations of the recipient's 
family (n = 15) and an unrelated friend (n = 1). Results: With an average 
follow-up of I year the overall survival is 75%. For the five patients followed up 
for at least 1 year, mean forced vital capacity was 80.6%, forced expiratory 
volume in 1 second was 75.6%, mid-forced expiratory flow was 64%, and 
diffusing lung capacity corrected for alveolar volume was 73% of predicted. For 
those patients with primary pulmonary hypertension, preoperative hemody- 
namics revealed mean pressures as follows: blood pressure 84.8 mm Hg, right 
atrial pressure 7.8 mm Hg, pulmonary artery pressure 71.3 mm Hg, pulmonary 
capillary wedge pressure 9.5 mm Hg, cardiac index 2.9 L/min per square meter, 
and pulmonary vascular resistance index 22.8 Wood units. Postoperative 
hemodynamics revealed a mean blood pressure of 84.3 mm Hg, right atrial 
pressure of 2.7 mm Hg, pulmonary artery pressure of 16 mm Hg, pulmonary 
capillary wedge pressure of 7.3 mm Hg, cardiac index of 4.2 L/min per square 
meter, and pulmonary vascular esistance index of 1.9 Wood units. Conclu- 
sions: Early results of living-donor bilateral lobar transplantation for 
diseases other than cystic fibrosis have resulted in satisfactory survival and 
pulmonary function. Additionally, patients with severe primary pulmonary 
hypertension have had dramatic normalization of their hemodynamics despite 
the limited amount of lung tissue transplanted. We believe that the data from 
this small cohort experience compares favorably with our larger series with 
cystic fibrosis and supports an expanded role for living-donor lobar transplan- 
tation in patients with alternate indications. (J Thorac Cardiovasc Surg 1997; 
114:917-22) 
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S ince the first attempts at clinical lung transplan- tatmn more than three decades ago, dramatic 
improvements in surgical technique, organ preser- 
vation, prevention and treatment of acute rejection, 
and management  of infection have occurred. As the 
indications and number  of referrals for lung trans- 
plantation have grown, the availability of donor 
organs has failed to significantly increase. As a 
consequence of this supply and demand mismatch, 
an increasing number  of patients have died while on 
the recipient waiting list. With this in mind, our 
group investigated the concept of clinical living- 
donor lobar transplantation. 1 The majority of our 
experience in this field has involved patients with 
cystic fibrosis. To date, we have per formed 42 
bilateral lobar transplants in this populat ion with a 
1-year survival of 73.8%. Given these results in an 
extremely challenging group of recipients with 
Pseudomonas andAspergillus in addition to all of the 
nonpulmonary complications of cystic fibrosis, we 
expanded our indications to include potential recip- 
ients with other diagnoses. We report on our early 
experience with our first eight patients receiving 
living-donor bilateral lobar transplants for indica- 
tions other than cystic fibrosis. 
Patients and methods 
Recipient selection. From November 1993 to March 
1997, eight bilateral living-donor transplants were per- 
formed in patients with diagnoses other than cystic fibro- 
sis. The indications (Table I) included primary pulmonary 
hypertension, postchemotherapy pulmonary fibrosis, 
bronchopulmonary d splasia, idiopathic pulmonary fibro- 
sis, and obliterative bronchiolitis (presumed to be from a 
viral origin). Three of the patients were adults, with a 
mean age of 30.3 years (range 19 to 40 years), and five 
were children, with a mean age of 12.4 years (range 9 to 15 
years). This cohort included only one male patient (idio- 
pathic pulmonary fibrosis). The patients all had severe 
progressive deterioration i clinical status, with or without 
a specific acute decline, and an expectation that a cadav- 
eric allograft would not be available in time. Of the eight 
patients, three pediatric patients with end-stage primary 
pulmonary hypertension were referred from Japan, where 
cadaveric lung transplantation is not an option as a result 
of absence of brain death legislation. For the remaining 
five patients, the average time accumulated on the cadav- 
eric waiting list was 18 weeks (range 1 to 78 weeks) before 
they underwent living-donor lobar transplantation. 
The patients all required long-term supplemental oxy- 
gen, and the two patients with pulmonary fibrosis were 
ventilator-dependent receiving 100% inspired oxygen, of 
whom one was using a high-frequency jet ventilator. For 
the four patients without primary pulmonary hyperten- 
sion, the average preoperative carbon dioxide tension was 
92 mm Hg (range 64 to 120 mm Hg) and three patients 
were steroid-dependent. All four patients with primary 
pulmonary hypertension had systemic or near-systemic 
pulmonary artery pressures, massively dilated right atrial 
and ventricular chambers, severe tricuspid regurgitation, 
and syncopal episodes despite long-term epoprostenol 
(prostacyclin) therapy. One of the patients with primary 
pulmonary hypertension was on high-dose intravenous 
inotropic therapy for right Ventricular support and had a 
cardiac arrest immediately before the transplant opera- 
tion. All eight patients were either wheelchair- and bed- 
bound or hospital-bound before transplantation (Table 
II). The patients had no irreversible nd-organ damage 
other than their pulmonary disease. Institutional Review 
Board approval from the University of Southern Califor- 
nia and Childrens Hospital Los Angeles was initially 
obtained before considering a patient for the procedure. 
Currently, we do not require institutional review board 
approval as a result of the acceptance of this procedure by 
the transplant community. All patients underwent he 
appropriate pretransplant serologic and physiologic 
workup and satisfied the usual criteria for cadaveric lung 
transplantation at our institution, as previously de- 
scribed. 2 As with other organ transplant procedures, 
especially those in which a pediatric population is in- 
volved, the presence of a stable outpatient support struc- 
ture with functional coping mechanisms i mandatory. 
Donor selection. The 16 living donors selected for the 
eight recipients represented various combinations of ei- 
ther the recipient's family (mothers, n = 5; fathers, n = 5; 
brothers, n = 2; sisters, n = 2; and cousin, n = 1) or an 
unrelated friend (n = 1). Both psychosocial and physio- 
logic factors were extensively assessed. All potential do- 
nors were screened by an independent committee includ- 
ing a psychiatrist and social worker to safeguard against 
coercion, as well as by the transplant team to ensure donor 
comprehension of the procedure, risks, and outcomes. As 
previously described, the donor evaluation included arte- 
rial blood gas analysis, complete spirometry, ventilation/ 
perfusion scanning, chest roentgenogram, chest computed 
tomography, echocardiography, exercise treadmill stress 
testing (for male donors older than 45 years of age), and 
routine serologic and viral screening. 2 Histocompatibility 
antigen (HLA) typing was performed for the recipient and 
chosen donors but was not used to guide donor selection. 
The lobes donated were a right lower lobe (n = 7) or 
right middle lobe (n = 1) from one donor and the left 
lower lobe from the other donor (n = 8). The choice of 
which donor is used for either the right or left side and 
whether the right lower lobe (or rarely the middle lobe) is 
used is decided on the basis of the aforementioned testing 
and size matching considerations. The middle lobe is 
generally no longer considered and the standard proce- 
dure involves use of the right and left lower lobes. If an 
otherwise acceptable donor has a prior history of infec- 
tion, trauma, or thoracic surgery unilaterally, then the 
contralateral side is chosen. If all aspects are equal, then 
the larger donor is usually selected for donation of the 
right lower lobe. The average donor age was 39.4 years 
with a mean donor height of 168 cm and a mean donor 
weight of 73 kg. In comparison, the mean recipient height 
was 152 cm and the mean weight was 40 kg (Table IIl). 
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Table I. Primary diagnoses 
Patients Age 
Diagnoses (n = 8) (yr) 
Pulmonary hypertension 4 11, 12, 15, 15 
Idiopathic pulmonary fibrosis 1 40 
Postchemotherapy pulmonary 1 32 
fibrosis 
Bronchopulmonary d splasia 1 19 
Obliterative bronchiolitis 1 9 
Table II. Preoperative data and severity of illnes 
In hospital 
Preoperative steroid therapy 
Ventilator dependent 
High-frequency jet ventilation 
Mean Pco 2 (non-PPH patients) 
NYHA class IV 
4/8 (50%) 
3/8 (38%) 
2/8 (25%) 
1/8 (12.5%) 
92 mm Hg (range 64-120) 
8/8 (100%) 
Pco2, Carbon dioxide tension; PPH, primary pulmonary hypertension; 
NYHA, New York Heart Association. 
Operative procedures. The surgical and logistic aspects 
of the right and left donor lobectomy, the donor lobe 
back-table preservation technique, and the recipient bilat- 
eral pneumonectomy and bilateral lobar implantation 
have been previously described by our group. 1' 3, 4 
Recipient postoperative management and immunosup- 
pression. The immediate perioperative and postoperative 
management and immunosuppressive protocol (including 
our modified chest tube management) is also similar to 
our prior description i  the population with cystic fibro- 
sis. 4 The patient remains intubated with a single-lumen 
endotracheal tube for 72 hours with a positive end- 
expiratory pressure of 10 cm H20. This prolonged venti- 
latory support is provided in an attempt o minimize 
atelectasis and maintain optimal expansion of the lobes. 
In addition, as the entire cardiac output is now flowing 
through two relatively undersized lobes, the hope is that 
this ventilatory management will decrease pulmonary 
edema and reperfusion injury. Specific differences in 
management in this group not having cystic fibrosis in- 
clude an increased use of intravenous inotropic agents for 
right ventricular support in the patients with significant 
preoperative primary pulmonary hypertension. Empiric or 
culture-guided use of broad-spectrum antibiotics is less 
frequent in this group than in the cystic fibrosis group, 
who nearly universally harbor pathogenic bacterial or 
fungal species, or both. A noninduction immunosuppres- 
sive protocol with cyclosporine (INN: ciclosporin) or 
tacrolimus, azathioprine, and corticosteroids i used. 
More recently, mycophenolate mofetil has been used 
instead of azathioprine. Prednisone is tapered to achieve 
a dose of 0.5 mg/kg per day by the end of the first 
postoperative month. The dose is decreased every subse- 
quent month by 0.1 mg/kg until the patient has reached a
maintenance dose of 0.1 mg to 0.15 mg/kg per day. 
Cytomegalovirus (CMV) prophylaxis i given to all pa- 
tients receiving a CMV-positive donor lobe, regardless of 
preoperative recipient status. Our current protocol is 
intravenous ganciclovir at 6 mg/kg per day for 2 weeks 
followed by oral ganciclovir 3 gin/day for the first 6 
months. Prophylaxis for Pneumocystis carinii consists 
of trimethoprim-sulfamethoxazole (320/1600 rag) three 
times a week for the first year. As an outpatient, pul- 
monary function testing and chest roentgenography are 
performed with each clinic visit. Bronchoscopy with or 
without transbronchial biopsy is performed only when 
clinically indicated by symptoms, radiography, or a de- 
crease in spirometric results. 
Results 
With an average follow-up of 1 year (range I to 30 
months for all patients), survival probability was 
0.75 with a standard error of 0.15 according to 
Kaplan-Meier analysis (WinSTAT for Windows 
3.1). The two deaths (both at 1 month after the 
operation) occurred in the patient with idiopathic 
pulmonary fibrosis as a result of Aspergillus pneu- 
monia and in the patient with obliterative bronchi- 
olitis with nonspecific bilateral graft failure of un- 
clear origin (culture negative, rejection free, with 
dense infiltration of polymorphonuclear cells). All 
six of the remaining patients are highly functional 
with no limitations on their activities. Two mild 
rejection episodes have occurred, classified as grade 
A2 according to the International Society for Heart 
and Lung Transplantation grading system, in the six 
patients. Both episodes responded to an augmenta- 
tion in corticosteroid osing. Of note, the average 
number of HLA matches between recipient and 
donors was 2.75 (range 0 to 6) and mismatches was 
2.73 (range 0 to 6). There has been only one 
infection (in the six surviving patients) necessitating 
intravenous antimicrobial therapy involving CMV 
viremia in one of the patients after treatment for the 
aforementioned rejection episode. This responded 
completely to intravenous ganciclovir therapy. 
Postoperative spirometry revealed a gradual pro- 
gressive improvement in pulmonary function that 
tends to plateau by postoperative months 9 to 12. 
For the five patients followed up at least 1 year, 
mean forced vital capacity is 80.6% of predicted, 
mean forced expiratory volume in 1 second is 75.6% 
of predicted, mean mid-forced expiratory flow is 
64% of predicted, and mean diffusing lung capacity 
corrected for alveolar volume is 73% of predicted 
(Table IV). For the four patients with primary 
pulmonary hypertension, postoperative right heart 
catheterization revealed normal pressures and pul- 
monary vascular esistance. Preoperative (within 3 
months of transplantation) and postoperative h mo- 
9 2 0 Starnes et al. 
The Journal of Thoracic and 
Cardiovascular Surgery 
December 1997 
Table HI. Recipient and donor demographics 
Mean Range 
Recipient (n = 8) 
Adult (n = 3) 
Age (yr) 30.3 19-40 
Pediatric (n = 5) 
Age (yr) 12.4 9-15 
Height (cm) 152 135-170 
Weight (kg) 40 30-65 
Donors (n = 16) 
Age (yr) 39.4 21-49 
Height (cm) 168 150-185 
Weight (kg) 73 46-97 
Table IV. Postoperative pulmonary spirometry 
Mean (% predicted) Range (% predicted) 
FVC 80,6 52-97 
FEV~ 75.6 54-93 
FEF25/75 64.0 47-97 
DLCONA 73.0 58-85 
FVC, Forced vital capacity; FEV1, forced expiratory volume in 1 second; 
FEF2s/75, Mid-forced expiratory flow; DLCO/VA, diffusing lung capacity 
corrected for alveolar volume. 
dynamics are shown in Table V. Right atrial and 
ventricular chamber size and tricuspid valve regur- 
gitation normalized in all four patients. All six 
intermediate and long-term survivors are in New 
York Heart Association functional class I. 
Among the 16 donors, there were two complica- 
tions in the postoperative period. One donor of a 
right lower lobe had a persistent air leak, defined as 
greater than 10 days, which was managed conserva- 
tively with continuous uction for 14 days. Another 
donor of a left lower lobe required surgical reex- 
ploration on the first postoperative day for evacua- 
tion of a hematoma fter removal of a chest tube 
resulted in intercostal venous bleeding. Both donors 
otherwise did well with no additional morbidity. For 
those donors with at least 1 year's follow-up (n = 
10), compared with baseline values, spirometry re- 
vealed a mean decrease in forced vital capacity of 
15%, in forced expiratory volume in 1 second of 
13%, and in total lung capacity of 16%. All 16 
donors have resumed their normal activity and 
lifestyles. 
Discussion 
As a consequence of the steady progress that has 
been achieved in lung transplantation, the discrep- 
ancy between donor availability and the recipient 
Table ¥. Right heart catheterization results (n = 4 
patients) 
Preoperative Postoperative 
Mean Range Mean Range 
BP (ram Hg) 84.8 68-98 84.3 62-98 
RA (mm Hg) 7.8 2-14 2.7 0-8 
PA (mm Hg) 71.3 60-85 16.0 11-18 
PCWP (mm Hg) 9.5 7-11 7.3 5-12 
CI (L/min/m a) 2.9 1.9-3.4 4.2 3.2-5.5 
SVRI (Wood units/BSA) 28.6 16.9-44.2 21.6 17.4-24.1 
PVRI (Wood units/BSA) 22.8 16.2-32.1 1.9 1.1-2.7 
BP, Systemic blood pressure; RA, right atrial pressure; PA, pulmonary 
artery pressure; PCWP, pulmonary capillary wedge pressure; CI, cardiac 
index; SVR/, systemic vascular resistance index; PVR/, pulmonary vascular 
resistance index; BSA, body surface area. 
waiting list continues to increase. Although the field 
of living-donor lobar transplantation is still rela- 
tively new, our experience in this aspect of pulmo- 
nary transplantation has not only resulted in an 
increase in the number of available allografts but, 
more important, has made them available in an 
expedient fashion. This has been life-saving for 
those potential recipients who are in rapidly deteri- 
orating condition and will either become unsuitable 
candidates or die before an organ becomes avail- 
able. In our region, the mean waiting time for 
cadaveric double lung transplantation is 12 months 
for pediatric patients and 20 months for adult 
patients. The majority of our experience in the field 
of living-donor lobar transplantation has involved 
recipients with end-stage cystic fibrosis. Our prior 
work in that extremely challenging patient popula- 
tion has demonstrated the safety and reproducibility 
of the procedure, with recipient outcomes compara- 
ble with those with conventional cadaveric double 
lung transplantation. 4-6To date, our experience with 
bilateral iving-donor lobar transplants in patients 
with cystic fibrosis has resulted in a 1-year actuarial 
survival of 73.8%. This is despite the severity of 
illness of this group and the urgent nature of the 
transplant for most of the recipients. 
In an attempt o expand the indications for this 
procedure to include patients with diagnoses other 
than cystic fibrosis, we now report on our early expe- 
rience with eight patients with end-stage pulmonary 
disease from different causes. The cohort consisted of 
pediatric and adult recipients with primary pulmonary 
hypertension, postchemotherapy pulmonary fibrosis, 
bronchopulmonary d splasia, idiopathic pulmonary 
fibrosis, and obliterative bronchiolitis. Three of those 
patients were moribund going into the operating 
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room. Each recipient received two lobes from various 
combinations of their family members or, in one case, 
from an unrelated friend. With two deaths from infec- 
tious causes, the 1-year survival was 75%. All six 
remaining survivors have had excellent functional out- 
come with a relatively low rejection and infection rate 
at 1-year follow-up. Postoperative spirometry has re- 
vealed excellent pulmonary function. The four patients 
with primary pulmonary hypertension all had end- 
stage disease with significant right heart failure, tricus- 
pid regurgitation, and markedly dilated right-sided 
chambers, despite maximal medical therapy including 
long-term epoprostenol (prostacyclin). After trans- 
plantation, cardiac size and function and hemodynam- 
ics all completely normalized. Similar to the postoper- 
ative hemodynamics seen in our cystic fibrosis 
population, the normal right heart catheterization 
results confirm the capability o f tw  0 pulmonary lobes 
to handle the entire cardiac output. This is particularly 
important if patients with underlying diseases resulting 
in severe pulmonary hypertension are considered as 
candidates in view of their markedly reduced preop- 
erative right ventricular function. The spirometric and 
hemodynamic results reflect the clinical picture of 
these recipients who have returned to an unrestricted, 
active lifestyle. 
The complications een in the cohort of donors 
continues to be relatively mild and have occurred 
with an incidence comparable with that observed in 
our larger series. With more than 100 lobectomies 
per formed in both related and unrelated living 
donors, the short- and long-term morbidity has been 
consistently low. We continue to follow these data 
(a s well as quality of life surveys) extremely closely 
because we strongly believe that donor outcome is 
as important as, if not more important han, recip- 
ient outcome. 
The data from this small cohort experience in 
patients with end-stage pulmonary disease from 
causes other then cystic fibrosis compare favorably 
with our larger series with cystic fibrosis. We believe 
this report  combined with our overall experience 
supports an expanded role for l iving-donor lobar 
transplantation in patients with alternate indica- 
tions. 
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Discuss ion 
Dr. G. Alec Patterson (St. Louis. Mo j. Dr. Starnes and 
his group deserves credit for introducing and expanding 
the role of living-related onor transplantation for pa- 
tients with lung diseases amenable to transplantation who 
will not survive long enough to obtain a cadaveric donor. 
We know that the mortality rate for patients with cystic 
fibrosis on transplant waiting lists is approximately 30% in 
some centers. We also know that patients with pulmonary 
fibrosis and pulmonary hypertension may have an even 
higher mortality rate on the waiting list. Therefore. I
believe that living-related donor transplantation does 
represent a reasonable option for selected patients if 
results can be achieved that equal cadaveric transplanta- 
tion. 
I have a number of observations and questions which I 
would like to address to Dr. Starnes regarding this initial 
experience. The mortality rate of 25% is higher than that 
of standard transplantation i experienced programs. I 
suspect hat this relates to recipient selection rather than 
to technical details of the operation. I would like your 
comments. 
Donor follow-up is critical in this procedure. How do 
you obtain follow-up information on these donors, partic- 
ularly from those donors whose lobes were transplanted 
into recipients who died in the perioperative period? 
Finally, suitable donor lungs are obviously difficult to 
identify, yet in th e Los Angeles area, despite the presence 
of active heart transplant programs, it seems to me that 
there is a very small number of cadaveric lung transplants 
being performed. Can you comment on the number of 
transplants performed using standard cadaveric donor 
lungs from your own_ region. Could you also speculate on 
whether the active living-related lung transplant program 
somehow diminishes the enthusiasm of regional organ 
procurement organizations to procure suitable cadaveric 
lungs? 
Dr. Starnes. Dr. Patterson, thank you very much for 
those comments. Your contributions to the field have 
been enormous, and I really take the opportunity to 
answer your question s with some insight into what you 
have contributed. 
The mortality rate of 25% is higher than in a large 
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cadaveric series of papers, but I think there are two 
problems. First. our "n" is small. With two deaths in a 
group of eight, the mortality rate is 25% immediately. The 
preoperative evaluation showed that these patients were 
critically ill. They were dying. Some of our patients who 
have the opportunity to wait at home for a cadaveric 
donor often are in better condition. These patient selec- 
tion issues probably increased our mortality rate. 
We monitor our donors very carefully. We do a survey 
at 1 year and we do a survey again at 2 years. The obvious 
question asked is. "Would you do it again?" The respons e 
to that has been overwhelmingly about 95% "yes." The 
5% that said that they would have to think about it or 
absolutely they would not do it again are those individuals 
that had donated a lobe to a nonsurvivor. We have found 
that we have had no long-term complications that have 
affected the quality of life in the donors. They are all back 
at work and doing the things that they were able to do 
before the operation. In terms of outcomes, we have not 
had a negative problem. 
Your points regarding the suitability of donor lungs and 
cadaveric lungs are well taken. The Los Angeles area is 
huge, and we get too few cadaveric lungs from it. I do not 
think that the impact of our program has biased the 
number of cadaveric donor organs that become available. 
however. Some of our issues are that we have large county 
hospitals erving a lot of John Does. and we cannot find 
family members to allow us to go forward with organ 
procurement. Now that our two organ procurement orga- 
nizations are working in conjunction, I hope to be able to 
improve that and increase the number of donors in our 
area. 
Dr. Douglas J. Mathisen (Boston, Mass.). Dr. Starnes. 
would you comment on the HLA status of this group? 
How does this compare with the cystic fibrosis popula- 
tion? Do you think the viral infections are different from 
the bacterial infections that patients with cystic fibrosis 
have in terms of: suitability for transplantation? 
Dr. Starnes. HLA matching in particular we have 
looked at and detailed. What we would anticipate is a 
fairly standard haploid match, particularly if it was coming 
from parents. In point of fact, the number of matches 
turned out to be about 2.7. and the number of mismatches 
about 2.7. If you evaluated the rejecting lobe versus the 
nonrejecting lobe. the HLA matching did not seem to play 
an important role, except in an occasional brother or 
sister, in whom we have had a five- and six-antigen match 
where it obviously did play a role. Anything less than a 
four-antigen match did not seem to affect the Outcome in 
terms of rejection. 
Some differendes arise in comparing viral illness versus 
bacterial illness, particularly in the pediatric age group. 
Some of these children come in with organisms, uch as 
the adenoviral nd parainfluenza organisms, for which we 
do not have effective therapy. We have actually canceled 
transplants because of a nasal swab and a preliminary 
report of the viruses that wer e growing. I cannot remem- 
ber cancelling a cystic fibrosis case because of a bacteria or 
flora once the patient was on our list. I do think there are 
some differences there. 
Dr. Stefano Nazari (Pavia, Italy). Have you had any 
bronchial healing complications? If so, is there any differ- 
ence in  the incidence of this complication between the 
adult and the pediatric patient? 
Dr. Starnes. Of the total experience of 52 patients, we 
have had one bronchial complication. It was a stenosis 
that We have treated with balloon dilation. We have not 
had to use a stent. Living-don0r organs are somewhat 
different from cadaveric organs because we are taking a 
lobe, and the bronchus and the collaterals to that bron- 
Chus are in much closer proximity to the !ung tissue. 
Obviously, bY definition, the length of the bronchial stump 
in the lobar transplant is very short. That probably as 
much as anything has decreased our incidence of bron- 
chial healing complications. 
Dr. David J. Sugarbaker (Boston, Mass.). In terms of 
your surveillance, because of the two immunologic make- 
ups of the donor lobes, are yo u required to obtain a 
transbronchial biopsy specimen from each lobe at the 
time? 
Dr. Starnes. Yes. What we have found is that the lobe 
that reject s initially tends to be the lobe that rejects in the 
future, but we Still survey bot h sides. 
Dr. Sugarbaker. Has that increased your complication 
rate from transbronchial biopsies in the follow-up period? 
Dr. Starnes. It has not, but we do not do routine 
biopsies. We base our biopsies On spirometry data. Also, 
we have noted that the tendency for bleeding after 
transbronchial biopsies in the lobar group is a little higher, 
I guess because there is more blood flow through the lobe. 
